Serum Institute of India Pvt. Ltd.
Serum Institute of India is dedicated to developing vaccines that meet the specific needs of different segments of the global population, including collaborations with international agencies. Its mission is to provide protection from birth onwards through innovative vaccine development, research, social responsibility initiatives, and green energy projects. The company is the world's largest vaccine manufacturer by volume, producing over 1.5 billion doses and supplying to around 170 countries. It has a strong focus on affordability, quality, and social impact, with extensive achievements, awards, and collaborations in the vaccine and biopharmaceutical sectors.
Industries
Nr. of Employees
Very Large (1000+)
Serum Institute of India Pvt. Ltd.
Patents
Method for removal of impurities from bacterial capsular polysaccharide based preparations
US-12180527-B2
View DetailsCombination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
US-12090195-B2
View DetailsMethods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
US-11793869-B2
View DetailsMethod for removal of impurities from bacterial capsular polysaccharide based preparations
US-11739356-B2
View DetailsStable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
US-11660333-B2
View Details
Method for removal of impurities from bacterial capsular polysaccharide based preparations
US-12180527-B2
View DetailsCombination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
US-12090195-B2
View DetailsMethods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
US-11793869-B2
View DetailsMethod for removal of impurities from bacterial capsular polysaccharide based preparations
US-11739356-B2
View DetailsStable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
US-11660333-B2
View DetailsProducts
Hexavalent combination pediatric vaccine (DTP, HepB, IPV, Hib)
Combination vaccine for active immunization of infants against diphtheria, tetanus, pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b in a three-dose primary schedule with booster recommendations.
Recombinant protein VLP malaria vaccine
Recombinant, adjuvanted malaria vaccine comprising a circumsporozoite-derived antigen expressed as virus-like particles in yeast.
Quadrivalent recombinant HPV vaccine
Quadrivalent recombinant human papillomavirus vaccine covering multiple serotypes for prevention of HPV-related disease.
Adjuvanted recombinant nanoparticle COVID-19 vaccine
Adjuvanted recombinant protein nanoparticle vaccine formulation developed for SARS-CoV-2, including variant-adapted formulations.
Adenoviral vector COVID-19 vaccine (recombinant viral vector)
Recombinant adenoviral vector-based SARS-CoV-2 vaccine used for primary immunization against COVID-19.
Live attenuated oral rotavirus vaccine (freeze-dried and liquid)
Live attenuated oral vaccine for prevention of rotavirus gastroenteritis, available in freeze-dried and liquid oral presentations.
Hexavalent combination pediatric vaccine (DTP, HepB, IPV, Hib)
Combination vaccine for active immunization of infants against diphtheria, tetanus, pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b in a three-dose primary schedule with booster recommendations.
Recombinant protein VLP malaria vaccine
Recombinant, adjuvanted malaria vaccine comprising a circumsporozoite-derived antigen expressed as virus-like particles in yeast.
Quadrivalent recombinant HPV vaccine
Quadrivalent recombinant human papillomavirus vaccine covering multiple serotypes for prevention of HPV-related disease.
Adjuvanted recombinant nanoparticle COVID-19 vaccine
Adjuvanted recombinant protein nanoparticle vaccine formulation developed for SARS-CoV-2, including variant-adapted formulations.
Adenoviral vector COVID-19 vaccine (recombinant viral vector)
Recombinant adenoviral vector-based SARS-CoV-2 vaccine used for primary immunization against COVID-19.
Live attenuated oral rotavirus vaccine (freeze-dried and liquid)
Live attenuated oral vaccine for prevention of rotavirus gastroenteritis, available in freeze-dried and liquid oral presentations.
Services
Execution of GLP-compliant preclinical studies and GCP-compliant clinical trials, including toxicology studies and staged clinical evaluation.
Manufacture, packaging and international distribution of vaccines in multiple presentations and dose formats, supporting national immunization programmes and international procurement agencies.
Inbound and outbound technology transfer, process scale-up and contract manufacture of vaccine components and finished-dose products to support partner supply commitments.
Rapid scale-up and prioritized production services for outbreak response, including expedited manufacturing, regulatory engagement and logistic support for emergency immunization programs.
Partnership-based support for developing adjuvanted vaccine candidates, formulation optimization and execution of early-phase clinical trials in collaboration with external partners.
Preparation and electronic submission of regulatory dossiers to national and international agencies and support for WHO prequalification processes.
Execution of GLP-compliant preclinical studies and GCP-compliant clinical trials, including toxicology studies and staged clinical evaluation.
Manufacture, packaging and international distribution of vaccines in multiple presentations and dose formats, supporting national immunization programmes and international procurement agencies.
Inbound and outbound technology transfer, process scale-up and contract manufacture of vaccine components and finished-dose products to support partner supply commitments.
Rapid scale-up and prioritized production services for outbreak response, including expedited manufacturing, regulatory engagement and logistic support for emergency immunization programs.
Partnership-based support for developing adjuvanted vaccine candidates, formulation optimization and execution of early-phase clinical trials in collaboration with external partners.
Preparation and electronic submission of regulatory dossiers to national and international agencies and support for WHO prequalification processes.
Expertise Areas
- Industrial-scale vaccine manufacturing
- Pandemic and outbreak manufacturing surge capacity
- Recombinant subunit and VLP vaccine platforms
- Polysaccharide-protein conjugate vaccine development
Key Technologies
- Bioreactor-based cell culture (mammalian and yeast systems)
- Virus-like particle (VLP) production
- Adenoviral and other viral vector manufacturing
- Recombinant protein nanoparticle vaccine platforms
News & Updates
Construction of a new research facility at Oxford University, UK, supported by Serum Institute of India.
The company signs a memorandum of understanding with DNDi to develop a new treatment for dengue in low- and middle-income countries.
The company becomes the first to submit a prequalification dossier to WHO.
UNICEF announced a long-term supply agreement with Serum Institute of India for COVID-19 vaccines, including technology transfer from AstraZeneca and Novavax.
Dr. Cyrus Poonawalla, Chairman and Managing Director of Serum Institute of India, accompanied by Natasha Poonawalla, called on Vice President of India and apprised him about the company's progress.
Serum Institute of India began supplying COVISHIELD vaccine to neighboring and key partner countries as part of India's Mission 'Vaccine Maitri'.
Construction of a new research facility at Oxford University, UK, supported by Serum Institute of India.
The company signs a memorandum of understanding with DNDi to develop a new treatment for dengue in low- and middle-income countries.
The company becomes the first to submit a prequalification dossier to WHO.
UNICEF announced a long-term supply agreement with Serum Institute of India for COVID-19 vaccines, including technology transfer from AstraZeneca and Novavax.
Dr. Cyrus Poonawalla, Chairman and Managing Director of Serum Institute of India, accompanied by Natasha Poonawalla, called on Vice President of India and apprised him about the company's progress.
Serum Institute of India began supplying COVISHIELD vaccine to neighboring and key partner countries as part of India's Mission 'Vaccine Maitri'.